Agomab Therapeutics NV of Belgium has raised $89 million in new capital to advance a pipeline of candidate products for fibrotic disorders. Announced on 25 October, the Series D round brings total funds raised from investors to more than $320 million since the company’s launch in 2017. Agomab’s newest investors are Sanofi SA and Invus, a US private equity company. Existing investors include Fidelity Management & Research Co and EQT Life Sciences.
